American Cancer Society urges prostate cancer screening for men

The society now proactively recommends screening every two years for men at average risk aged 50–69, and annually at ages 45–69 for higher-risk men, including Black men and those with a strong family history.
In this article
The American Cancer Society recommends prostate-specific antigen (PSA) blood tests every two years for men at average risk of prostate cancer from ages 50–69, guideline co-author Andrew Wolf said in an interview with The Conversation. The recommendations, announced on 12 November 2026, replace the society’s previous advice to discuss with a healthcare provider whether screening was right for the individual.
For men at higher risk, including Black men and men with a strong family history of prostate cancer, the society recommends annual screening from ages 45–69. A strong family history means one family member diagnosed before age 65 or multiple family members diagnosed at any age, Wolf said.
Wolf is a physician and professor emeritus of medicine at the University of Virginia and volunteers as chair of the society’s Guideline Development Group. His disclosure says his opinions do not necessarily reflect the society’s views.
Who should be screened
Men with one family member diagnosed at age 65 or older should be screened every two years from ages 45–69, Wolf said. At ages 70–74, the society recommends discussing whether to continue with a healthcare provider: the benefit is uncertain, and the decision depends on personal preferences, overall health and life expectancy. It recommends against screening after age 74 because the potential harms are likely to outweigh the benefits.
Wolf said Black men have approximately two-thirds higher risk of developing prostate cancer than white men and are more likely to have advanced disease at diagnosis. He said genetic, environmental, social and healthcare-access factors likely contribute. An affected close relative, such as a parent, sibling or child, also raises risk. The guidelines do not cover screening for people with high-risk genetic mutations such as BRCA2.
The society also recommends against a digital rectal exam for screening because it is less effective than the PSA test, Wolf said. The exam may still help assess an elevated PSA level or prostate-related symptoms.
Why the advice changed
Wolf said evidence has grown that PSA screening reduces the risk of prostate cancer death and diagnosis with cancer that has spread more than previously thought. He also cited developments that reduce harms, including false-positive results and the diagnosis and treatment of tumors unlikely to cause long-term harm.
Two large trials published in 2009 had contributed to uncertainty: a US study found no benefit, while a European study initially found a relatively small one. Wolf said almost 90% of the US trial’s control group, who were not supposed to be screened, actually received screening, and many participants with abnormal results did not follow up. Most people assigned to standard care in the European trial did not receive a PSA test, making it a clearer comparison, he said.
Wolf said more than two decades of follow-up in the European trial showed a 13% reduction in the risk of death from prostate cancer, with about 500 men screened for each death averted.
Benefits, risks and costs
PSA is a protein made by prostate cells, and its level can rise because of cancer or other conditions. An elevated result alone does not diagnose cancer. Wolf said an abnormal follow-up MRI scan or biomarker test may lead to a prostate biopsy, which can diagnose it.
Biopsies can cause discomfort, bleeding and occasionally infection, Wolf said. A slow-growing tumor may lead to active surveillance, or periodic biopsies, MRI scans or both; he said these can be inconvenient and cause anxiety. Surgery or radiation can cause sexual, urinary and bowel problems. Declining screening also means giving up an opportunity to find cancer at an early stage, when the chance of cure is high, he said.
Wolf expects most insurers to cover screening under the new recommendations, but said patients may have out-of-pocket costs for further tests ordered after an abnormal PSA result.
The U.S. Preventive Services Task Force’s 2018 position advises clinicians not to screen unless a patient prefers to proceed, after finding the benefits and harms closely balanced. Wolf said both sets of guidelines call for patients to be informed of the benefits, risks and limitations. The task force is updating its guidance and could move closer to the society’s position, he said.
Follow AveNews
Earlier in Science
EarthFifth Canadian soldier dies after Wainwright grass fire
The Canadian Armed Forces confirmed that Private William Douglas Dal Bianco died on 13 November from injuries sustained in the October 17 fire. It said 24 personnel remained in hospital as of 14 November.
2 min
SpaceSpaceX catches Starship after orbit, but loses booster
The launch tower caught Ship 42 on 14 November after its return from orbit, a first for the spacecraft. The planned catch of the Super Heavy booster was aborted, and the booster exploded over the Gulf of Mexico. Earlier coverage described an offshore splashdown.
2 min
HealthWorld Health Organization issues first adult type 1 diabetes guidelines
The guidelines recommend several daily insulin injections and regular glucose checks for adults across all settings, including emergencies and places with limited resources.
2 min
